STVN
Get informed when a big investor buys or sells
+ FollowOvervalued by 80.5% based on the discounted cash flow analysis.
| Market cap | $5.35 Billion |
|---|---|
| Enterprise Value | $5.77 Billion |
| Dividend Yield | $0.06 (0.32%) |
| Earnings per Share | $0.49 |
| Beta | 0.78 |
| Outstanding Shares | 273,003,694 |
| P/E Ratio | 33.64 |
|---|---|
| PEG | 590.05 |
| Price to Sales | 4.73 |
| Price to Book Ratio | 3.78 |
| Enterprise Value to Revenue | 4.81 |
| Enterprise Value to EBIT | 28.89 |
| Enterprise Value to Net Income | 40 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.35 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.39%▼ 15.93% |
|---|---|
| Total Invested | $19.26M▼ 96.86% |
| Investors Holding | 8▼ 128.00% |
No data
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...